At the crossroads of vaginal health and disease, the genome sequence of Lactobacillus iners AB-1

Authors

Emma Allen-Vercoe, University of Guelph
Gregor Reid
Norman Viner
Gregory B. Gloor
Susy Hota
Peter Kim
Christine Lee
Kieran O'Doherty
Stephen J. Vanner
J. Scott Weese
Elaine O. Petrof

Document Type

Article

Publication Date

1-1-2012

Journal

Canadian journal of gastroenterology = Journal canadien de gastroenterologie

Volume

26

Issue

7

First Page

457

Last Page

462

URL with Digital Object Identifier

10.1155/2012/213828

Abstract

A working group from across Canada comprised of clinician and basic scientists, epidemiologists, ethicists, Health Canada regulatory authorities and representatives of major funding agencies (Canadian Institutes of Health Research and the Crohn's and Colitis Foundation of Canada) met to review the current experience with fecal microbial therapy and to identify the key areas of study required to move this field forward. The report highlights the promise of fecal microbial therapy and related synthetic stool therapy (together called 'microbial ecosystems therapeutics') for the treatment of Clostridium difficile colitis and, possibly, other disorders. It identifies pressing clinical issues that need to be addressed as well as social, ethical and regulatory barriers to the use of these important therapies.